Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214)

Authors

Jiaxin Yang (ORCID: https://orcid.org/0000-0003-4211-7832)
Hairong Yao (ORCID: https://orcid.org/0000-0002-9060-4603)
Yonglan He (ORCID: https://orcid.org/0000-0003-2567-9710)
Dongyan Cao (ORCID: https://orcid.org/0000-0003-4253-832X)
Junjun Yang
Ninghai Cheng (ORCID: https://orcid.org/0000-0001-8458-0142)
Shikai Liu (ORCID: https://orcid.org/0000-0002-6027-4439)
Peng Peng (ORCID: https://orcid.org/0009-0001-8344-0356)
Yang Xiang (ORCID: https://orcid.org/0000-0002-9112-1021)
Zhilin Yuan
Chen Li (ORCID: https://orcid.org/0000-0002-4405-8306)

Institutions

Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Peking Union Medical College Hospital (CN)
National Clinical Research Center for Digestive Diseases (CN)
Cangzhou Central Hospital (CN)

Publication Details

Journal: Journal of Gynecologic Oncology
Published: 2024-10-28
DOI: https://doi.org/10.3802/jgo.2025.36.e44
Citations: 3
Primary Topic: Colorectal Cancer Treatments and Studies
Type: article
Field-Weighted Citation Impact: 0.85

Funders

Shanghai Junshi Biosciences
National Natural Science Foundation of China

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214)

Jiaxin Yang, Hairong Yao, Yonglan He, Dongyan Cao et al.

Oct 28, 2024

3 citations

Journal of Gynecologic Oncology

Colorectal Cancer Treatments and Studies

0.85

article

Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214)

Jiaxin Yang, Hairong Yao, Yonglan He, Dongyan Cao, Junjun Yang, Ninghai Cheng, Shikai Liu, Peng Peng, Yang Xiang, Zhilin Yuan, Chen Li

October 28, 2024article en

3 citations

Abstract

No abstract available for this paper.

Journal of Gynecologic OncologyVol. 36(3)

Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking Union Medical College Hospital (CN), National Clinical Research Center for Digestive Diseases (CN), Cangzhou Central Hospital (CN)

Shanghai Junshi Biosciences, National Natural Science Foundation of China

Good health and well-being

Openalex Percentile: Top 22%

Colorectal Cancer Treatments and Studies

0.85

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214) — Jiaxin Yang, Hairong Yao, et al. · Journal of Gynecologic Oncology (2024) | TGRS Research Map | TGRS